Background: Lung cancer is the oncological disease with the highest mortality worldwide. Health-related quality of life is severely compromised in the majority of patients. While the efficacy of early palliative psychosocial therapy has been demonstrated in several recent studies, appropriate therapy modules could so far not be integrated into daily practice of care. Therefore, an additive multimodal treatment concept for oncological centers was drafted: the Additive anthroposophic integrative medicine Cancer Concept of Early supportive or Palliative lung cancer Treatment (ACCEPT®). Patients and Methods: The first module consisted of a 3-month health education program, the second module was a concept of psychosocial interventions, and the third module was a supervised home training program. Between 2017 and 2018, 20 lung cancer patients (UICC IIIB/IV) were included and randomly assigned to treatment (n = 10) or a waiting control group (n = 10). The treatment group started ACCEPT® for 3 months immediately after diagnosis and received also standard oncological care (SOC) while the waiting control group received SOC only for 3 months, followed by ACCEPT® after this period. Health-related quality of life, disease management, disease-specific symptoms, and feasibility of the ACCEPT® were monitored at 4 time points. Results: 7 out of 10 patients in the treatment group (3 dropped out) and 6 out of 10 in the waiting control group (4 died during the intervention) completed treatment. Discussion/Conclusion: Lung cancer patients with high symptom load may benefit from ACCEPT®. The feasibility of this adjunctive therapy was demonstrated. The combination of SOC and ACCEPT® is feasible and applicable to a heterogeneous patient group and should be further evaluated with respect to efficacy and dosing.
Complement Med Res

中文翻译：

---

ACCEPT®：肺癌姑息治疗的补充人智学计划——基本原理和随机可行性研究

背景：肺癌是全球死亡率最高的肿瘤疾病。大多数患者的健康相关生活质量严重受损。虽然最近的几项研究已经证明了早期姑息性心理社会治疗的功效，但迄今为止还不能将适当的治疗模块整合到日常护理实践中。因此，为肿瘤中心起草了一个附加的多模式治疗概念：早期支持性或姑息性肺癌治疗的附加人智整合医学癌症概念（ACCEPT®）。患者和 方法：第一个模块包括为期 3 个月的健康教育计划，第二个模块是心理社会干预的概念，第三个模块是有监督的家庭培训计划。2017 年至 2018 年期间，20 名肺癌患者 (UICC IIIB/IV) 被纳入并随机分配到治疗组 ( n = 10) 或等待对照组 ( n = 10)。治疗组在诊断后立即开始 ACCEPT® 3 个月，并接受标准肿瘤护理 (SOC)，而等待对照组仅接受 SOC 3 个月，在此期间后接受 ACCEPT®。在 4 个时间点监测与健康相关的生活质量、疾病管理、疾病特异性症状和 ACCEPT® 的可行性。结果：治疗组10例患者中有7例（退出3例）和等待对照组10例患者中有6例（干预期间死亡4例）完成治疗。讨论/结论：具有高症状负荷的肺癌患者可能受益于 ACCEPT®。证明了这种辅助治疗的可行性。SOC 和 ACCEPT® 的组合是可行的，适用于异质患者群体，应进一步评估疗效和剂量。
补充医学资源